Ad hoc announcement pursuant to Art. 53 LR

SKAN will miss sales and profit expectations for 2025 – order intake and backlog are developing very positively and laying a strong foundation for 2026

Allschwil, November 6, 2025 – The SKAN Group conducted a planned review of its project portfolio in the last days. This assessment identified delays in several projects that will affect sales and earnings in the current financial year. The SKAN Group will therefore not meet its sales and profit expectations for 2025. Order intake continues to develop very positively and lays the foundation for a strong 2026 financial year, which will be significantly above 2024 and 2025. The medium-term targets are confirmed.

The SKAN Group now expects net sales for the 2025 financial year to decline by a high single-digit percentage compared to the previous year. The EBITDA margin for 2025 is expected to be in the low double-digit range. This is significantly below the guidance for 2025, which had targeted net sales growth in the mid-single-digit range and an EBITDA margin between 14% and 16%.

The reason for this is that additional projects have been postponed since the summer, pushing significant portions of the highest turnover month of December into 2026. As a result of the lost sales, this year’s EBITDA is correspondingly lower.

The SKAN Group’s order intake continues to develop very positively in the current financial year, with particular demand for filling lines for oncology applications and biotechnologically produced injectable large molecules. It is already foreseeable that the order backlog will very likely reach a new high by the end of the year. This provides a strong basis for a successful 2026 financial year.

The medium- and long-term growth prospects for the SKAN Group remain positive, supported by structural market growth, a strong global competitive position, and a solid project pipeline. SKAN is therefore confirming its medium-term targets: It expects net sales to grow at an annual rate in the mid- to upper teens. The EBITDA margin is to be gradually increased to the upper teens in the mid-term, with potential for further increase beyond the mid-term period.

Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13

Financial calendar:

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs close to 1700 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, France, Slovenia, Croatia, Japan, the USA and Brazil.